BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37943568)

  • 1. Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors.
    King J; Ashkar R; Kesler K; Althouse SK; Hanna NH; Einhorn LH; Adra N
    JAMA Oncol; 2024 Jan; 10(1):132-134. PubMed ID: 37943568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors.
    King JM; Cheng M; Kesler K; Ashkar R; Althouse SK; Hanna NH; Einhorn LH; Adra N
    J Clin Oncol; 2023 Aug; 41(23):3939-3944. PubMed ID: 36758196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.
    Ghodoussipour S; Daneshmand S
    Urol Clin North Am; 2019 Aug; 46(3):389-398. PubMed ID: 31277733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group.
    Gerdtsson A; Thor A; Grenabo Bergdahl A; Almås B; Håkansson U; Törnblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Sagstuen Haugnes H; Engen Andreassen K; Melsen Larsen S; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
    Eur Urol Oncol; 2022 Apr; 5(2):235-243. PubMed ID: 33750683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
    Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
    Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
    Besse B; Grunenwald D; Fléchon A; Caty A; Chevreau C; Culine S; Théodore C; Fizazi K
    J Thorac Cardiovasc Surg; 2009 Feb; 137(2):448-52. PubMed ID: 19185168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.
    Gupta A; Feifer AH; Gotto GT; Kraus D; Motzer R; Bosl GJ; Bajorin D; Feldman DR; Carver B; Sheinfeld J
    Urology; 2011 Mar; 77(3):655-9. PubMed ID: 21377010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.
    Paffenholz P; Nestler T; Hoier S; Pfister D; Hellmich M; Heidenreich A
    Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?
    Riggs SB; Burgess EF; Gaston KE; Merwarth CA; Raghavan D
    Oncologist; 2014 May; 19(5):498-506. PubMed ID: 24718515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
    Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
    Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: the danger of postchemotherapy laparoscopic retroperitoneal lymph node dissection for nonseminomatous testicular carcinoma.
    Spermon JR; Witjes JA
    J Endourol; 2008 May; 22(5):1013-6. PubMed ID: 18429687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.
    Wood DP; Herr HW; Heller G; Vlamis V; Sogani PC; Motzer RJ; Fair WR; Bosl GJ
    J Urol; 1992 Dec; 148(6):1812-5; discussion 1815-6. PubMed ID: 1331547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
    Nguyen CT; Stephenson AJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Postchemotherapy Surgery in Germ Cell Tumors.
    Chéry L; Dash A
    Urol Clin North Am; 2015 Aug; 42(3):331-42. PubMed ID: 26216820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach.
    Sonneveld DJ; Sleijfer DT; Koops HS; Keemers-Gels ME; Molenaar WM; Hoekstra HJ
    Cancer; 1998 Apr; 82(7):1343-51. PubMed ID: 9529027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
    Paffenholz P; Pfister D; Heidenreich A
    Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.
    Woldu SL; Moore JA; Ci B; Freifeld Y; Clinton TN; Aydin AM; Singla N; Laura-Maria K; Hutchinson RC; Amatruda JF; Sagalowsky A; Lotan Y; Arriaga Y; Margulis V; Xie Y; Bagrodia A
    Eur Urol Oncol; 2018 Aug; 1(3):242-251. PubMed ID: 31058267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
    Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
    J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.